LifeVantage Co. (NASDAQ:LFVN - Get Free Report) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 231,100 shares, an increase of 13.8% from the September 30th total of 203,000 shares. Currently, 2.3% of the shares of the company are short sold. Based on an average trading volume of 94,300 shares, the short-interest ratio is currently 2.5 days.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in LFVN. Hillsdale Investment Management Inc. acquired a new stake in LifeVantage in the first quarter valued at $76,000. Hantz Financial Services Inc. acquired a new stake in LifeVantage in the second quarter valued at $91,000. Ritholtz Wealth Management increased its holdings in LifeVantage by 62.0% in the third quarter. Ritholtz Wealth Management now owns 28,666 shares of the company's stock valued at $346,000 after purchasing an additional 10,974 shares during the period. Empowered Funds LLC increased its holdings in LifeVantage by 8.1% in the first quarter. Empowered Funds LLC now owns 76,203 shares of the company's stock valued at $461,000 after purchasing an additional 5,742 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in LifeVantage by 2.8% in the first quarter. Acadian Asset Management LLC now owns 228,088 shares of the company's stock valued at $1,378,000 after purchasing an additional 6,121 shares during the period. 35.32% of the stock is currently owned by institutional investors and hedge funds.
LifeVantage Stock Performance
Shares of LFVN stock traded down $0.51 during trading on Tuesday, hitting $12.98. The company had a trading volume of 172,827 shares, compared to its average volume of 59,519. The firm has a market capitalization of $164.86 million, a P/E ratio of 46.36 and a beta of 0.84. The stock's 50-day moving average price is $10.68 and its 200 day moving average price is $8.27. LifeVantage has a one year low of $4.20 and a one year high of $14.71.
LifeVantage (NASDAQ:LFVN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 28th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.07). LifeVantage had a net margin of 1.47% and a return on equity of 27.85%. The company had revenue of $48.93 million during the quarter.
LifeVantage Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 17th. Shareholders of record on Monday, September 9th were given a dividend of $0.04 per share. The ex-dividend date of this dividend was Monday, September 9th. This represents a $0.16 annualized dividend and a yield of 1.23%. LifeVantage's dividend payout ratio is currently 57.14%.
LifeVantage Company Profile
(
Get Free Report)
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LifeVantage, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeVantage wasn't on the list.
While LifeVantage currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.